Neoadjuvant chemotherapy and perioperative cardiotoxicity Authors: Yingzhou Tu, Suli Zhou, Haoran Wang, Peiyao Zhang, Cunming Liu, Changmao Zhu, Chun Yang Published: 2024 ABSTRACT AbstractMalignant tumors constitute a major threaten to human health and are among the most serious public health challenges both in China and globally. Many patients with malignancy require neoadjuvant chemotherapy prior to surgery. Neoadjuvant chemotherapy, which involves administering systemic chemotherapy before local treatment (such as surgery or radiotherapy) for malignant tumors, offers several benefits. These include tumor shrinkage, the reduction of the pathological stage of primary lesions and metastatic lymph nodes, and the early elimination of possible smile metastases. This pre-operative therapy is advantageous as it paves the way for more successful surgical treatment. Nonetheless, research indicates that neoadjuvant chemotherapy may lead to cardiotoxicity, resulting in myocardial ischemia, arrhythmia, arterial hypertension, and even heart failure. Therefore, the use of precision anesthesia, combined with cardioprotective strategies during surgery, is essential. By employing these measures, the surgical procedure can be performed more effectively, ultimately contributing to improved long-term survival outcomes for patients. The focus of this review is to discuss the typical treatment protocols for neoadjuvant chemotherapy, the underlying mechanisms of cardiotoxicity, and the importance of monitoring, assessing, and safeguarding perioperative cardiac function in surgical patients who have undergone neoadjuvant chemotherapy. By examining these aspects, this review aims to offer insights that can guide anesthesia management during the perioperative period for cancer surgery patients.Keywords: Neoadjuvant chemotherapy, Radiotherapy, Perioperative cardiotoxicity, Anesthesia, Surgery Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with its incidence continuing to rise. Among the current treatment modalities—surgery, immunotherapy, chemotherapy, and radiotherapy—chemotherapy plays a pivotal role. Notably, neoadjuvant chemotherapy (NAC), which involves systemic chemotherapy administered prior to surgery or radiotherapy for locally advanced tumors, has gained significant attention. NAC offers several advantages, including tumor downsizing, pathological downstaging of primary and metastatic sites, and early eradication of micrometastases.1 These benefits not only facilitate subsequent surgical interventions but also provide insights into chemotherapy sensitivity. Despite these promising outcomes, accumulating evidence highlights the cardiotoxic effects of NAC, manifesting as myocardial ischemia, arrhythmias, hypertension, myocardial dysfunction, and even heart failure. Alarmingly, such toxicities may persist long after the completion of treatment, posing long-term risks to survivors. Implementing precision anesthesia combined with cardioprotective strategies during surgery is critical to ensuring procedural success and improving long-term survival outcomes. This review focuses on the cardiotoxicity of commonly used chemotherapeutic agents for different cancers and explores potential strategies for myocardial protection in the perioperative setting. Typical neoadjuvant chemotherapy regimens Breast cancer Neoadjuvant chemotherapy has become a crucial component in the treatment of breast cancer. Specifically, for Triple-Negative Breast Cancer (TNBC) patients, the standard neoadjuvant chemotherapy regimen typically involves anthracyclines and taxanes (Fig. 1). Additionally, platinum-based agents may be incorporated into the neoadjuvant chemotherapy regimens. According to the guidelines set forth by the American Society of Clinical Oncology (ASCO), patients with TNBC exhibiting clinically node-positive and/or at least T1c disease should be offered a neoadjuvant regimen that includes both anthracyclines and taxanes.2 The Brightness study demonstrated that combining taxanes with platinum drugs, followed by anthracyclines, significantly increased the rate of pathological complete response (pCR) and improved the prognosis in comparison to the sequential administration of taxanes followed by anthracyclines.3 In line with the recommendations provided by the European Society of Medical Oncology (ESMO) Guidelines, carboplatin is suggested as a part of the neoadjuvant chemotherapy regimen.4 For the treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer, the current standard neoadjuvant chemotherapy regimen involves conventional systemic chemotherapy combined with trastuzumab therapy.5 Patients with node-positive or high-risk node-negative status, as well as those with HER2-positive tumors, should be administered neoadjuvant therapy consisting of anthracycline- and taxane-based regimens, or non-anthracycline-based regimens, in addition to trastuzumab.2 Several prospective clinical trials, such as TRAIN2, KRISTINE, and TRYPHENA, have demonstrated that combining trastuzumab with pertuzumab, taxanes, and platinum drugs results in a higher pCR rate.6, 7, 8 Comparative Chemotherapy Strategies for Different Cancer Types. NSCLC: Non-small cell lung cancer; TNBC: Triple negative breast cancer; HER2: Human Epidermal Growth Factor Receptor 2; GC: Gemcitabine + Cisplatin; IC: Induction chemotherapy; CCRT: Concurrent chemoradiotherapy. Gastrointestinal cancer According to clinical trials such as MAGIC and FNCLCC/FFCD, the European Society for Medical Oncology (ESMO) recommends neoadjuvant chemotherapy for patients with gastric cancer who have a clinical stage of ≥cI.B (cT2N0M0 or cT1N1M0).9, 10 The ESMO advocates the use of two- or three-drug regimens consisting of platinum and fluorouracil. Recently, several clinical trials, including PRODGY, FLOT, and RESOLVE, have investigated the efficacy of various combination regimens. The findings from these studies suggest that the following regimens may be suitable for neoadjuvant chemotherapy in gastric cancer: DOS (docetaxel + oxaliplatin + S-1), FLOT (fluorouracil + leucovorin + oxaliplatin + docetaxel), and SOX (S-1 + oxaliplatin).11, 12, 13 The latest guidelines from the Chinese Society of Clinical Oncology (CSCO) recommend neoadjuvant chemotherapy regimens such as FOLFOX (oxaliplatin + 5-fluorouracil), XELOX (oxaliplatin + capecitabine), SOX, FLOT, and DOS.14 However, due to the limited availability of high-quality prospective clinical studies, there is currently no consensus on a standardized neoadjuvant chemotherapy regimen for gastric cancer. For patients with resectable colon cancer, the National Comprehensive Cancer Network (NCCN) recommends FOLFOX or XELOX as the preferred neoadjuvant treatment regimen.15 Due to the limited data supporting this treatment option, the evidence for FOLFIRI chemotherapy and FOLFIRINOX is relatively scarce and is therefore categorized as 2B.16 The neoadjuvant period typically lasts 2–3 months. Lung cancer In the case of non-small cell lung cancer (NSCLC), neoadjuvant or adjuvant treatment options include cisplatin in combination with docetaxel, etoposide, gemcitabine, or vinorelbine.17 For non-squamous NSCLC, the preferred neoadjuvant or adjuvant treatment is cisplatin plus pemetrexed, while cisplatin plus gemcitabine or docetaxel is the first-line choice for squamous NSCLC.17 Osteosarcoma Osteosarcoma, a prevalent primary bone malignancy among individuals in the pediatric and adolescent age group, is conventionally managed using a perioperative treatment protocol referred to as MAP (high-dose methotrexate, doxorubicin, and cisplatin).18 This regimen is widely acknowledged as the global benchmark for patients below the age of 40.18 Gynecologic cancer Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer. The results of a large international multicenter phase III randomized controlled trial, GCIG INTERLACE, suggest that induction chemotherapy (IC) + CCRT can significantly improve progression-free survival(PFS) and overall survival(OS) in patients with locally advanced cervical cancer, and the IC+CCRT of paclitaxel combined with carboplatin weekly therapy is expected to become the new standard treatment for locally advanced cervical cancer.19 Systemic platinum-paclitaxel combined chemotherapy is usually recommended to improve the prognosis of patients with advanced ovarian cancer after satisfactory tumor reduction. This regimen is also used as a standard treatment for ovarian cancer. A pilot study of pamiparib in combination with surufatinib in the neoadjuvant treatment of patients with advanced ovarian cancer was reported at the 2023 ESMO Annual Meeting, suggesting that intermittent tumor cytoreductive therapy followed by neoadjuvant therapy with pamiparib plus surufatinib is beneficial for the prognosis of patients.20 Bladder cancer To date, three studies have reported the application of neoadjuvant chemotherapy combined with immunotherapy in patients with muscle-invasive bladder cancer (MIBC). In a phase II study investigating the combination of GC (gemcitabine + cisplatin) and pembrolizumab for the treatment of MIBC, 22 out of 39 patients achieved downstaging to pathological stage pT2N0 or lower, with 14 patients achieving pT0N0.21 In another phase II study combining GC with atezolizumab, 27 out of 39 patients (69 %) experienced pathological downstaging to pT2N0 or lower, including 16 patients (41 %) who reached pT0N0.22 The third phase II study utilized GC combined with durvalumab as neoadjuvant therapy, followed by durvalumab as adjuvant therapy, showing a three-year overall survival rate of 81 %.23 Cardiotoxicity Over the years, the term “cardiotoxicity” has been used to describe various specific disease entities, highlighting the need for a standardized definition. The cardiotoxicity of cancer therapies is commonly classified into different types: type I or primary (toxic) cardiomyopathy, which involves direct (endogenous) cardiomyocyte damage; type II or secondary (indirect) cardiomyopathy, which includes alterations in perfusion, innervation, or hormonal milieu; and type III cardiomyopathy or myocarditis, which involves inflammatory cell infiltration in the myocardium.24 Different drugs are associated with different types of cardiotoxicity (Table 1). For example, anthracyclines induce type I cardiomyopathy, while drugs like 5-fluorouracil (5-FU) and capecitabine are associated with type II cardiomyopathy.24 Cyclophosphamide is a classic example of a conventional chemotherapy drug that can induce myocarditis.24 Table 1Summary of Cardiotoxicity Types and Mechanisms Associated with Chemotherapy Drugs. Dox: Doxorubicin; 5-FU: 5-Fluorouracil; Type I: Primary (toxic) cardiomyopathy; Type II: Secondary (indirect) cardiomyopathy; Type III: Myocarditis.Table 1ClassDrugCardiotoxicity TypeMechanismAnthracyclinesDoxType IROS production, DNA damage, mitochondrial dysfunction, various cell death pathways.Fluoropyrimidine5-FUType IICoronary vasospasm, endothelial damage, cardiotoxic metabolites.Alkylating AgentsCyclophosphamideType IIIOxidative stress, inflammation, apoptosis from metabolites.Platinum DrugsCisplatinType I/IIOxidative stress, inflammation, cardiomyocyte apoptosis.Targeted DrugsTrastuzumabType I/IIOxidative stress, mitochondrial impairment, inhibition of protective pathways.BevacizumabPrimarily hypertension Summary of Cardiotoxicity Types and Mechanisms Associated with Chemotherapy Drugs. Dox: Doxorubicin; 5-FU: 5-Fluorouracil; Type I: Primary (toxic) cardiomyopathy; Type II: Secondary (indirect) cardiomyopathy; Type III: Myocarditis. Anthracyclines Anthracyclines are cytostatic antibiotics, used to treat several adult and pediatric cancers, such as solid tumors, leukemia, lymphomas and breast cancer.25, 26 The risk of developing cardiomyopathy with anthracyclines is largely dose-dependent.25 Anthracycline-induced cardiotoxicity(AIC) is traditionally classified into three forms: acute cardiotoxicity (heart damage that occurs during and within 1 week of aggressive cancer treatment), chronic early-onset cardiotoxicity (within 1 year after completion of treatment), and chronic late-onset cardiotoxicity (1 year after completion of treatment).27, 28, 29, 30 The acute form manifests primarily with electrocardiographic (ECG) changes and arrhythmias, mainly sinus tachycardia though supraventricular tachycardia, heart block and ventricular arrhythmias may also occur. These can lead to palpitations, presyncope and syncope, and even cardiac arrest, and occasionally with reversible cardiac dysfunction, even acute heart failure and peri-/myocarditis.24, 30 Pathologically, acute anthracycline-associated cardiotoxicity resembles acute toxic myocarditis, characterized by cardiomyocyte damage, inflammatory infiltrates, and interstitial edema.31 Chronic early-onset cardiotoxicity, the most common form of anthracycline-induced cardiotoxicity, presents as a dilated-hypokinetic cardiomyopathy with progressive evolution towards heart failure.32 Histopathologically, chronic anthracycline-related cardiotoxicity is characterized by vacuole formation, myofibril dropout, necrosis, and fibrosis.33 Fluoropyrimidine 5-Fluorouracil(5-FU) is the third most commonly used chemotherapeutic agent for the treatment of solid malignancies worldwide.34 It is the second most common chemotherapeutic drug associated with cardiotoxicity after anthracyclines.34 The risk of cardiotoxicity is higher with continuous infusions compared to bolus regimens, indicating that plasma exposure over time primarily influences the development of cardiotoxicity.35 Unlike the direct myocardial toxicity of anthracyclines, the toxic effect of fluorouracil on the heart mainly manifests as coronary vasospasm and direct toxic effects on endothelial cells.36, 37 However, reports have also indicated direct injury to cardiomyocytes similar to anthracycline-related damage.24 The most common presentation of 5-FU-related cardiotoxicity is chest pain, which can present as atypical chest pain, angina on exertion or rest, and acute coronary syndromes, including myocardial infarction.34, 37, 38, 39 Uncommon cardiotoxic manifestations include arrhythmias, myocarditis and pericarditis, heart failure and peripheral arterial toxicity (Raynaud’s phenomenon and ischaemic stroke).34, 40 Cyclophosphamide Cyclophosphamide (CP), an alkylating agent, is a valuable anticancer drug utilized in bone marrow transplantation, rheumatoid arthritis, lupus erythematosus, multiple sclerosis, neuroblastoma and other cancers.41 However, its dose-related cardiotoxicity poses a significant limitation to its use.41 Alongside its antineoplastic properties, CP also exhibits marked immunosuppressive effects, making it useful in preventing graft rejection following organ transplantation.42 At high doses, CP and other alkylating agents can induce pulmonary veno-occlusive disease and myocarditis.24, 25 Additionally, the use of CP has been associated with acute pericarditis, pericardial effusion and Raynaud phenomenon.43, 44 Platinum Platinum drugs represent a highly effective class of broad-spectrum antineoplastic agents and are widely utilized in the clinical treatment of diverse solid tumors. Although rare, incidences of cardiotoxicity have been observed in clinical practice, which show a significant correlation with the concentration and dosage of treatment. Clinical manifestations of its cardiotoxicity include electrophysiological changes, arrhythmias, myocarditis, pericarditis, mild blood pressure fluctuations, myocardial infarction, cardiomyopathy, cardiac failure, angina, and congestive heart failure.45 Targeted drugs Vascular-targeted agents, such as bevacizumab, trastuzumab, and pertuzumab, play a critical role in neoadjuvant chemotherapy regimens. As opposed to anthracyclines, trastuzumab-induced cardiotoxicity(TIC) is generally considered to be reversible, non-dose-dependent, and not present in all patients.46 Left ventricular dysfunction (LVD) and heart failure (HF) are common and severe consequences of cardiotoxicity in cancer treatment.46 Additionally, patients receiving trastuzumab may experience arrhythmias, sick sinus node syndrome, and atrial flutter.47 Conversely, bevacizumab-induced cardiotoxicity is primarily characterized by hypertension, with an incidence ranging from 4 % to 35 % and occurring at any stage of the treatment, and is dose-dependent.48, 49 Bevacizumab has also been associated with thromboembolism, including venous thrombosis (deep vein thrombosis, pulmonary embolism) and arterial thrombosis (cerebrovascular events, myocardial infarction).50 Mechanisms Anthracycline The primary mechanism of anthracycline-induced cardiotoxicity involves oxidative stress, DNA damage, mitochondrial damage, and various forms of cell death, such as autophagy and apoptosis. In the case of doxorubicin (Dox), cardiotoxicity appears to occur through increased reactive oxygen species (ROS) production and lipid peroxidation in cardiac tissue, with various enzymes such as nitric oxide synthase (NOS), NADPH oxidase (NOX), mitochondrial-dependent ROS production, and others playing a role in activating oxidative stress.51 Dox exerts its anticancer effects by inhibiting topoisomerase II (Top2), causing DNA damage and leading to cancer cell death. However, a similar effect can occur in cardiomyocytes and result in functional myocyte loss or even irreversible heart injury.52, 53 Interference with mitochondrial processes is a prominent factor contributing to the molecular and cellular determinants of Dox cardiotoxicity, leading to the development of cardiomyopathy.54 Dox concentration-dependent mitochondrial toxic effects have been reported, including mitochondrial superoxide accumulation, decreased mitochondrial membrane potential, decreased mitochondrial DNA copy number, and mitochondrial ultrastructural alterations.55 Additionally, Dox initially induces autophagy and later blocks it, resulting in the accumulation of undegraded autophagosomes and autolysosomes that exacerbate the damage in cardiomyocytes and lead to their death.56 Recently, emerging regulated cell death pathways, including ferroptosis, necroptosis, and pyroptosis, have been implicated in Dox-induced cardiotoxicity.56 Various cell types, including cardiac progenitor cells, cardiac fibroblasts, and endothelial cells, have been identified as potential additional targets in the pathogenic process of anthracycline-induced cardiomyopathy, creating a complex and intriguing scenario.57 Fluoropyrimidine The pathogenesis of 5-FU cardiotoxicity remains unknown and appears to involve multiple mechanisms. A primary theory for 5-FU-related myocardial ischemia is coronary artery vasospasm, which was directly observed during coronary angiography in some cohort studies during the 1980s and 1990s.34, 58, 59, 60 Mosseri discovered that 5-FU induces coronary artery vasoconstriction through the protein kinase C pathway, independent of vascular endothelial cell damage in animal models.61 Moreover, 5-FU can directly damage the coronary vascular endothelium and lead to abnormal endothelial cell function. In a 2012 prospective study, von willebrand factor and proteinuria were found to increase following 5-FU-based chemotherapy, indicating a reversible global endothelial injury resulting from such treatment.62 Additionally, the metabolites of 5-FU with cardiotoxicity can directly damage cardiomyocytes. Alpha-fluoro-beta-alanine (FBAL), a metabolite of FU, is further catabolized into fluoroacetate, a compound known for its high cardiotoxicity.63, 64, 65 Cyclophosphamide Using an in vitro metabolomics approach in AC16 human cardiomyocytes, a study revealed that CP caused significant cytotoxicity on cardiac AC16 cells, while the metabolites of CP such as 4-hydroxycyclophosphamide and acrolein resulted in higher cytotoxic effects at the µM range.66 Cardiotoxic mechanism of CP or its metabolite consists of oxidative stress, nitrative stress, altered calcium homeostasis, formation of protein adduct that causes cardiomyocytes inflammation, apoptosis, cardiomyocytes swelling, nuclear splitting, vacuolization and alteration in signaling pathways.41 Acrolein activates p38MAPK and c-Jun N-terminal kinase signaling pathways in response to oxidative stress, upregulates the protein expression of Bax/Bcl-2 and cleaves Caspase-3 to trigger mitochondrial apoptosis, and activates the DNA damage response signaling pathway to induce cytotoxicity.67 Though endothelial nitric oxide synthase(eNOS) is generally cardioprotective and antihypertrophic, acute acrolein exposure can suppress eNOS activation, whereas chronic acrolein exposure may decrease overall eNOS abundance.68 Targeted drug Although the mechanism responsible for targeted drug-induced cardiac effects is not yet fully understood, studies suggest it may be associated with several processes. Like anthracycline, trastuzumab induces oxidative stress, autophagy and impairs mitochondrial function. In the heart, neuregulin-1 (NRG-1) triggers HER-4/HER-4 homodimerization and HER-4/HER-2 heterodimerization on cardiomyocytes to induce protective pathways in response to stress, such as exposure to other cardiotoxic agents like Dox.69, 70 Trastuzumab binds to HER2 protein to inhibit HER2 signaling on tumor cells and cardiomyocytes. This prevents heterodimerization of nearby HER3/4 receptors in response to NRG-1 signals, thereby inhibiting the protective pathways, leading to the excessive accumulation of ROS and destruction of cardiomyocytes in the presence of excess organic oxygen species, which can lead to cardiac insufficiency.69, 71 Mohan demonstrated that trastuzumab leads to the phosphorylation of HER1/2 subunits and the activation of Erk and in turn results in up-regulation of mammalian target of rapamycin(mTOR) signaling pathway and subsequently inhibition of autophagy in primary cardiomyocytes.72 Trastuzumab-mediated inhibition of autophagy resulted in the increased production of ROS in cardiomyocytes.72 Increased ROS production destroys mitochondrial function by a loss of mitochondrial membrane integrity and release of cytochrome C.73, 74 Trastuzumab has also been found to encourage pro-inflammatory effects in the heart, triggering fibrosis and pathogenic tissue remodeling, although insufficient evidences exist supporting this perspective.69 Similar to the other chemotherapy drugs mentioned above, cisplatin’s cardiotoxic effects are associated with oxidative stress, inflammation, and apoptosis of cardiomyocytes.75, 76, 77, 78 Risk factors Many studies have explored risk factors associated with cardiotoxicity from neoadjuvant chemotherapy in order to improve risk identification. Gender differences have been identified as one of the risk factors in the toxic effects. The menopausal state and age of female patients are key determinants of sex-specific differences in AIC, with pre-pubertal females at increased risk, adult males at increased risk, and elderly males and postmenopausal women at similar risk.79 In pediatric cancer patients, female sex is considered a significant risk factor for AIC, while anecdotal evidence suggests that female sex protects against AIC in adult cancer patients.80 Age has also been identified as a risk marker, with patients less than 5 years old or more than 65 years old having an increased risk for AIC.32 A study conducted in Kuwait demonstrated that breast cancer patients aged 60 years and above were at a 4-fold higher risk of developing a ≥ 10 % decline in their left ventricular ejection fractions(LVEF) compared to younger patients during trastuzumab treatment.81 The association between age and fluoropyrimidine-induced cardiotoxicity remains controversial.34, 82 Dyslipidemia, diabetes, and obesity are comorbidities significantly associated with an increased incidence of symptomatic cancer treatment-related cardiotoxicity.82, 83, 84, 85, 86, 87 Additionally, prior anthracycline use and the cumulative anthracycline dose are risk factors associated with trastuzumab-related cardiotoxicity.88, 89, 90 Cranial irradiation exposure has also been reported as an additional risk factor for AIC.91 Pre-existing cardiovascular risk factors such as arterial hypertension (AH), elevated baseline blood pressure, and ventricular sigmoid septum are also reported as risk factors for cancer therapy.92, 93, 94 The mode of administration can also affect the probability of cardiotoxicity, with continuous infusions associated with higher risk compared to bolus regimens in fluoropyrimidine-induced cardiotoxicity.35 Furthermore, low baseline LVEF and greater LVEF decline post-anthracycline are both independent predictors of TIC.95 In conclusion, risk factors for the development of cardiotoxicity include gender, age, previous anthracycline exposure, coronary artery disease, hypertension, diabetes, smoking, low-normal baseline EF, and obesity(Fig. 2). Overview of Myocardial Injury in Surgical Patients Post-Neoadjuvant Chemotherapy: Drugs, Risk Factors, Assessment, and Protection. NPs: Natriuretic peptides; hs-cTn: High-sensitive cardiac troponins; GDF-15: Growth differentiation factor 15; TTE: Transthoracic echocardiography; STE: Speckle tracking echocardiography; CMR: Cardiac magnetic resonance; BBs: Beta-blockers; ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker. Although many studies have identified a range of risk parameters for chemotherapy-related cardiotoxicity, these factors have not been routinely and systematically assessed. To predict the 3-year risk of HF or cardiomyopathy, Ezaz et al. developed a 7-factor risk score model based on the presence or absence of diabetes, age, coronary artery disease, renal failure, atrial fibrillation/ flutter, or prior exposure to any type of chemotherapy to stratify patients into low, moderate and high-risk groups, using Surveillance, Epidemiology and End Results (SEER)-Medicare data.96 Building on this model, Rushton et al. propose an approach to cardiotoxicity risk stratification that incorporates the score developed by Ezaz et al. with cardiac biomarkers, such as troponin I and with strain imaging, to further enhance sensitivity in identifying patients at high risk of treatment-related cardiac dysfunction.97 Similarly, Abdel et al. developed a point-based scoring system to estimate cardiovascular prognosis, employing competing risks methodology. The model effectively classified patients across a broad range of risks, with those in the highest risk score decile having > 40-fold higher incidence of major adverse cardiovascular events compared to women in the lowest decile.98 In addition, Wang et al. established a predictive nomogram model based on chemotherapy cycle, age, BMI, and use of target therapy for 5-FU induced cardiotoxicity.82 Importantly, new baseline cardiovascular risk assessment tools in cancer patients scheduled to receive cardiotoxic cancer therapies have been proposed from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.99 Through these various approaches, researchers aim to improve the identification and stratification of cancer patients at risk of chemotherapy-related cardiotoxicity, ultimately enhancing patient care and outcomes. While these models assist in identifying high-risk patients, their implementation in clinical practice still faces challenges. For example, cardiac biomarkers and strain imaging require additional equipment and technical expertise, which may not be available in all settings. Furthermore, some models, such as Wang et al.’s predictive nomogram, may only be effective in specific chemotherapy regimens, making it challenging to integrate these tools in contexts involving multi-drug regimens or individualized treatments. Clinicians should select the most appropriate risk assessment tool based on the specific circumstances of the patient. For patients with multiple comorbidities or higher risk profiles, a combination of different assessment methods may be more reliable. For hospitals with limited resources, simpler and more accessible scoring systems may be preferred, while institutions with advanced technology can consider integrating biomarkers and imaging assessments for more comprehensive risk evaluation. Monitoring and assessment Assessment of cardiovascular risk factors helps identify high-risk patients and screen out subclinical patients with cardiotoxicity, thereby reducing the incidence of cardiotoxicity(Fig. 2). Serum biomarkers and cardiovascular imaging are important tools for clinicians to evaluate the cardiovascular disease risk of cancer patients. Serum biomarkers Cardiac biomarkers, although not routinely used in clinical practice, are reliable indicators for early screening and monitoring of cardiotoxicity. The most supported and superior cardiac biomarkers for diagnosis, monitoring, and prognostication of cardiovascular disease (CVD) are cardiac troponins (cTn) and natriuretic peptides (NPs).100 In patients treated with cardiotoxic cancer therapy, elevated troponins are associated with systolic dysfunction.101 A meta-analysis has suggested that high-sensitive cardiac troponins(hs-cTn) has a higher early diagnostic value compared to echocardiography for cancer therapy-related cardiotoxicity (CTRCD).102 In 2012, a study demonstrated that the combination of troponin and GLS in anthracycline-treated patients increased sensitivity for detecting cardiotoxicity.103 Furthermore, researchers have been exploring new biological markers for diagnosing adverse cardiac events caused by chemotherapy drugs. One study highlights myeloperoxidase as a potential candidate biomarker for predicting cardiotoxicity.104 Additionally, doubling of growth differentiation factor 15 and galectin-3 levels has been found to be associated with an increased risk of early anthracycline-induced cardiotoxicity.105 Another potential diagnostic and treatment tool for doxorubicin-induced cariotoxicity(DIC) is microRNAs, a type of non-coding RNA.106 Early alterations in circulating arginine-nitric oxide metabolites are also linked to a higher CTRCD rate.107 Finally, novel exploratory tools such as genetic testing, Omics technologies, human stem cell-derived cardiomyocytes, and artificial intelligence hold potential for predicting cancer therapy-related cardiotoxicity.108 Cardiovascular imaging Multi-gated acquisition (MUGA) scanning, echocardiography, cardiac magnetic resonance (CMR), and cardiac nuclear testing are common imaging tools for assessing cardiac function. Transthoracic echocardiography (TTE) is the preferred imaging technique for baseline risk stratification in 2022 ESC guidelines on cardio-oncology because it is non-invasive, radiation-free, and virtually implementable in any clinical scenery.25, 43 It provides accurate information regarding heart structure, function, and derived Doppler intracardiac hemodynamics.43 Three-dimensional echocardiography(3DE) has lower inter-, intra-observer, and test-retest variability compared to conventional two-dimensional echocardiography (2DE) biplane Simpson method.100 Speckle tracking echocardiography (STE) is another sensitive and promising diagnostic modality that provides global longitudinal strain (GLS), global circumferential strain (GCS), and global radial strain (GRS).109 Strain measurement with STE is capable of quantifying myocardial function regionally and identifying subtle and subclinical LV dysfunction.109 On the other hand, multi-gated acquisition (MUGA) scanning is a frequently used imaging modality for evaluating LVEF evolvement, but it has questionable accuracy, modest reproducibility, and limited information on structural cardiac dysfunction. Additionally, serial monitoring with MUGA results in cumulative radiation exposure. As a result, it is not recommended as a first-line cardiac imaging modality.109 Cardiac magnetic resonance (CMR) is a non-invasive imaging technique that assesses LV function, tissue characterization, and myocardial injury.110 It can determine LVEF and extracellular volume fraction (ECVF), as well as assess LV myocardial injury and help identify cardiotoxicity.110 In cases where CMR is not available, contraindicated, or provides equivocal results, cardiac nuclear imaging like fluorodeoxyglucose positron emission tomography (FDG-PET) can be used to assess for immune checkpoint inhibitor myocarditis.111 Overall, TTE, 3D echocardiography, STE, CMR, and cardiac nuclear testing are common imaging tools for assessing cardiac function, each with its own strengths and limitations in terms of accuracy, reproducibility, and information provided on cardiac dysfunction. Cardiac function can be evaluated through various imaging parameters. In clinical practice, cancer therapy-related cardiovascular toxicity is typically determined by a decrease in LVEF. However, relying solely on LVEF as a measurement of overall cardiac function may not be sufficient, as it often requires significant tissue function loss that is irreversible before it can be clinically detected.112 Therefore, it is necessary to develop strategies for identifying cardiac injury prior to the reduction in LVEF. One such strategy is the measurement of GLS, which has been shown by several researchers to be superior to LVEF in detecting early and subclinical myocardial dysfunction, with good repeatability.113, 114, 115, 116, 117 Monitoring GLS also allows for early detection of myocardial dysfunction and initiation of cardio-protective therapy in high-risk patients.118 However, like LVEF, GLS is influenced by load dependency. To overcome this limitation, non-invasive myocardial work quantification, combining strain measurements with left ventricular pressure, can provide a loading-independent evaluation of myocardial performance.119, 120, 121 Additionally, global circumferential strain (GCS) may serve as an additional marker of myocardial dysfunction, but further validation studies are needed.111 Lastly, recent studies suggest that computed tomography-derived extracellular volume fraction could be a valid imaging marker for detecting myocardial damage and preventing cardiotoxicity in cancer therapy patients.122 During preoperative screening, a focused history and examination, specifically exploring for signs and symptoms of cardiotoxicity, with consideration for a routine preoperative Electrocardiograph (resting tachycardia, ST-segment and T-wave changes; conduction disturbances and QT prolongation; and arrhythmias) and laboratory tests (troponins and N-terminal pro-B type natriuretic peptide) should be obtained.123 If cardiotoxicity is suspected, patients should be seen by a cardiologist for further evaluation and medical optimisation.123 Protection and treatment Conventional cardioprotective medications, including beta-blockers (BBs), angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), aldosterone antagonists, and statins, have been evaluated for their preventive or therapeutic effects on HF caused by cardiotoxicity induced by cancer therapy(Fig. 2). A systematic review and network meta-analysis of randomized controlled trials classified these medications according to drug type and found that aldosterone antagonists, ACEIs, statins, and BBs significantly improve left ventricular (LV) systolic function. Specifically, spironolactone, enalapril, and statin showed a significant cardioprotective effect. However, ARBs were found to have no cardioprotective effect and failed to improve LV ejection fraction (LVEF).124 In a randomized clinical trial conducted in patients with breast cancer undergoing anthracycline-based chemotherapy, it was concluded that ramipril and bisoprolol attenuate the decline in LVEF with a good safety profile. This benefit was maintained at 12 and 24 months for most patients.125 Another systematic review and meta-analysis focused on breast cancer patients receiving adjuvant trastuzumab and/or anthracyclines and found that beta-blockers (BBs), but not ACEI/ARBs, significantly and effectively preserved LVEF compared to placebo.126 However, the cardioprotective effects of carvedilol,127 candesartan128 or the combination of candesartan and carvedilol129 in anthracycline-treated patients still lack sufficient evidence, as assessed by several recent randomized controlled trials. Statins have anti-inflammatory properties and are being investigated for their potential role in preventing anthracycline-mediated cardiotoxicity. The STOP-CA trial found that atorvastatin can reduce the incidence of cardiac dysfunction in patients with lymphoma undergoing anthracycline-based chemotherapy.130 A propensity score-matched cohort study focused on women receiving anthracycline and/or trastuzumab-based chemotherapy for early breast cancer showed that statin-exposed individuals had a lower risk of hospital presentations for HF, although the reduction was not statistically significant for trastuzumab.131 Consequently, larger trials are needed to further evaluate the protective effects of these drugs. Dexrazoxane is currently approved in patients with high and very high CTRCD risk or who have already received high cumulative anthracycline doses, according to the 2022 ESC Guidelines on cardio-oncology.25 A systematic review and meta-analysis of randomized and nonrandomized trials on the efficacy of dexrazoxane in patients with breast cancer treated with anthracyclines, with or without trastuzumab, concluded that dexrazoxane reduced the risk of clinical heart failure and cardiac events, without significantly impacting cancer outcomes.132 Therefore, De Baat et al. suggest that it might be justifiable to use dexrazoxane in children and adults with cancer who are treated with anthracyclines, when the risk of cardiac damage is expected to be high.133 In recent years, several drugs have been identified as having potential cardioprotective effects. For instance, in 2023, Fan et al. developed a decoy exosome called Exo-TDN, which was modified with mesenchymal stem cell exosomes and a tetrahedral DNA nanostructure (TDN) abundant in "G-C." This engineered Exo-TDN-PCM was designed to specifically target cardiomyocytes and the injection of Exo-TDN-PCM demonstrated a significant reduction in Dox-induced cardiotoxicity.134 Telomerase gene therapy has also shown promise in protecting the heart from DOX-induced apoptosis and preserving cardiac function, as observed by Chatterjee et al.135 Moreover, yellow wine polyphenolic compound has been reported to protect against Dox-induced cardiotoxicity by modulating the gut microbiota.136 This finding highlights the potential of dietary polyphenols for cardiovascular disease treatment through microbiota regulation. Additionally, mito-TEMPO, a mitochondria-targeted antioxidant, has the potential to serve as a protective agent or adjuvant in combination chemotherapy by modulating mitochondrial oxidative stress.137 Finally, calycosin, the primary compound extracted from the traditional Chinese medicine Astragalus, has demonstrated cardioprotective effects in a zebrafish embryonic AIC model.138 Conclusions Neoadjuvant chemotherapy, widely used in treating malignancies like breast and bowel cancers, plays a vital role in lowering tumor stages and enhancing cancer resection rates, thus facilitating optimal surgical conditions. Nevertheless, it may precipitate cardiac complications to varying extents. Consequently, anesthesiologists should comprehensively assess and safeguard cardiac function throughout the perioperative phase to ensure procedural success. The preoperative assessment entails a comprehensive evaluation of the patient’s overall health status, medical history, laboratory tests, and test results to ensure the safety. If necessary, cardioprotective drugs should be administered to minimize the potential risks of perioperative cardiac adverse events and ensure a smooth operation. CRediT authorship contribution statement Yingzhou Tu: Writing – review & editing, Writing – original draft, Software, Resources, Methodology. Suli Zhou: Writing – original draft, Software, Resources, Methodology. Haoran Wang: Resources, Methodology. Peiyao Zhang: Resources, Methodology. Cunming Liu: Supervision, Resources. Changmao Zhu: Writing – review & editing, Writing – original draft, Resources, Conceptualization. Chun Yang: Writing – review & editing, Writing – original draft, Supervision, Resources, Funding acquisition, Conceptualization. Disclosure statement Not applicable. Ethical statement Not applicable. Funding This research received no external funding. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Chun Yang is an Editorial Board Member for Journal of Anesthesia and Translational Medicine and was not involved in the editorial review or the decision to publish this article. Acknowledgements The authors would like to express the deepest gratitude to all those who have supported us throughout the process of this paper. The authors are grateful to our colleagues and peers for their constructive criticism and encouragement. Contributor Information Changmao Zhu, Email: 2037419@qq.com. Chun Yang, Email: chunyang@njmu.edu.cn. Data availability All study data are included in the article. References Associated Data Data Availability Statement All study data are included in the article.